Neoadjuvant therapy in resectable pancreatic cancer: A promising curative method to improve prognosis

doi:10.4251/wjgo.v14.i10.1903

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4867)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-7) series.

Item

Count

PDF

202

WORD

HTML

2541

Figures (1-1)

257

Tables (1-7)

229

Sum=3302

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

372

Download

1193

Sum=1565

Oct 15, 2022 (publication date) through Nov 24, 2024

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastrointest Oncol. Oct 15, 2022; 14(10): 1903-1917
Published online Oct 15, 2022. doi: 10.4251/wjgo.v14.i10.1903

Table 2 Ongoing randomized controlled trials comparing surgery alone with neoadjuvant therapy followed by surgery for resectable pancreatic cancer

Trial name	NCT number	Phase	Status	Estimated enrollment	Treatment arm	Primary endpoint	Study start date	Estimated primary completion date	Estimated study completion date
ICI20-00047	NCT05181605	II/III	Not yet recruiting	116	FOLFIRINOX and SBRT with surgery	OS	January 2022	January 2023	December 2024
					Upfront surgery
CISPD-1	NCT03750669	II	Recruiting	416	nPt/GEM and mFOLFIRINOX with surgery	DFS	October 2018	October 2023	October 2024
					Upfront surgery
A021806	NCT04340141	III	Recruiting	352	mFOLFIRINOX with surgery	OS	July 2020	January 2026	November 2030
					Upfront surgery
PREOPANC	NCT04927780	III	Recruiting	378	mFOLFIRINOX with surgery	OS	September 2021	February 2026	July 2029
					Upfront surgery
AIO-PAK-0313	NCT02047513	II	Active, not recruiting	127¹	nPt/GEM with surgery	DFS	July 2015	April 2021²	October 2022³
					Upfront surgery
NorPACT-1	NCT02919787	II/III	Active, not recruiting	140	FOLFIRINOX with surgery	1-yr OS	September 2016	October 2022	April 2026
					Upfront surgery
NEOPAC	NCT01314027	III	Terminated	38¹	GEM/oxaliplatin with surgery	PFS	September 2009	December 2018²	May 2019³
					Upfront surgery
NEOPA	NCT01900327	III	Terminated	32¹	GEM and EBRT with surgery	3-yr survival rate	February 2014	November 2016²	July 2017³
					Upfront surgery
NEOPAC/IPC 2011-002	NCT01521702	III	Completed	2¹	GEM/Oxaliplatin with surgery	PFS	December 2011	February 2015²	February 2015³
					Upfront surgery
NEPAFOX	NCT02172976	II/III	Completed	40¹	FOLFIRINOX with surgery	mOS	November 2014	January 2020²	May 2020³
					Upfront surgery

¹Actual enrollment.

²Actual primary completion date.

³Actual study completion date.

SBRT: Stereotactic body radiotherapy; OS: Overall survival; nPt: Nab-paclitaxel; GEM: Gemcitabine; DFS: Disease-free survival; PFS: Progression-free survival; EBRT: External beam radiation.

Citation: Zhang HQ, Li J, Tan CL, Chen YH, Zheng ZJ, Liu XB. Neoadjuvant therapy in resectable pancreatic cancer: A promising curative method to improve prognosis. World J Gastrointest Oncol 2022; 14(10): 1903-1917
URL: https://www.wjgnet.com/1948-5204/full/v14/i10/1903.htm
DOI: https://dx.doi.org/10.4251/wjgo.v14.i10.1903